CoChat
Sign Up
Cited by 61

Opportunities for microRNAs in the crowded field of cardiovascular biomarkers

Halushka, Perry V., Goodwin, Andrew J., Halushka, Marc K.·2019·Annual Review of Pathology: Mechanisms of Disease
DOI 10.1146/annurev-pathmechdis-012418-012827PMC PMC6442682
Open this paper in CoChat — free account

Abstract

Cardiovascular diseases exist across all developed countries. Biomarkers that can predict or diagnose diseases early in their pathogeneses can reduce their morbidity and mortality in afflicted individuals. microRNAs are small regulatory RNAs that modulate translation and have been identified as potential fluid-based biomarkers across numerous maladies. We describe the current state of cardiovascular disease biomarkers across a range of diseases, including myocardial infarction, acute coronary syndrome, myocarditis, hypertension, heart failure, heart transplantation, aortic stenosis, diabetic cardiomyopathy, atrial fibrillation, and sepsis. We present the current understanding of microRNAs as possible biomarkers in these categories and where their best opportunities exist to enter clinical practice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-pathmechdis-012418-012827

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miRNAs demonstrate altered expression levels in disease states that may have biomarker potential.

    “They also demonstrate altered expression levels in disease states that may have biomarker potential [3, 4].”

    From A curated human cellular microRNAome based on 196 primary cell types (2022) · cites this paper as [4]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 129

  1. [1]Lewis BP, Burge CB, Bartel DP. 2005 Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15– 20 15652477
  2. [2]Pinzon N, Li B, Martinez L, Sergeeva A, Presumey J, 2017 microRNA target prediction programs predict many false positives. Genome Res. 27: 234– 45 28148562 PMC5287229
  3. [3]Cai Y, Yu X, Hu S, Yu J. 2009 A brief review on the mechanisms of miRNA regulation. Genom. Proteom. Bioinform 7: 147– 54 PMC5054406 20172487
  4. [4]Bauersachs J, Thum T. 2011 Biogenesis and regulation of cardiovascular microRNAs. Circ. Res 109: 334– 47 21778437
  5. [5]Kim VN. 2005 MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol 6: 376– 85 15852042
  6. [6]Kozomara A, Griffiths-Jones S. 2014 miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42: D68– 73 24275495 PMC3965103
  7. [7]Witwer KW, Halushka MK. 2016 Toward the promise of microRNAs—enhancing reproducibility and rigor in microRNA research. RNA Biol. 13: 1103– 16 27645402 PMC5100345
  8. [9]de Rie D, Abugessaisa I, Alam T, Arner E, Arner P, 2017 An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat. Biotechnol 35: 872– 78 28829439 PMC5767576
  9. [11]Backes C, Meder B, Hart M, Ludwig N, Leidinger P, 2016 Prioritizing and selecting likely novel miRNAs from NGS data. Nucleic Acids Res. 44: e53 26635395 PMC4824081
  10. [12]Backes C, Fehlmann T, Kern F, Kehl T, Lenhof HP, 2018 miRCarta: a central repository for collecting miRNA candidates. Nucleic Acids Res. 46: D160– 67 29036653 PMC5753177
  11. [13]Ludwig N, Becker M, Schumann T, Speer T, Fehlmann T, 2017 Bias in recent miRBase annotations potentially associated with RNA quality issues. Sci. Rep 7: 5162 28701729 PMC5507985
  12. [14]Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, 2015 A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome. Annu. Rev. Genet 49: 213– 42 26473382 PMC4743252
  13. [15]Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, 2010 Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev. 24: 992– 1009 20413612 PMC2867214
  14. [16]Wang X, Liu XS. 2011 Systematic curation of miRBase annotation using integrated small RNA high-throughput sequencing data for C. elegans and Drosophila. Front. Genet 2: 25 22303321 PMC3268580
  15. [17]Halushka MK, Fromm B, Peterson KJ, McCall MN. 2018 Big strides in cellular microRNA expression. Trends Genet. 34: 165– 67 29361313 PMC5834366
  16. [18]Fromm B, Domanska D, Hackenberg M, Mathelier A, Hoye E, 2018 MirGeneDB2.0: the curated microRNA gene database. bioRxiv 258749 10.1101/258749</bold></underline> · DOI
  17. [19]Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 2002 Identification of tissue-specific microRNAs from mouse. Curr. Biol 12: 735– 39 12007417
  18. [21]Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, 2004 An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. PNAS 101: 9740– 44 15210942 PMC470744
  19. [22]Halushka MK. 2016 MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome. J. Heart Lung Transplant 35: 543 27044533
  20. [23]Kent OA, McCall MN, Cornish TC, Halushka MK. 2014 Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 42: 7528– 38 24875473 PMC4081080
  21. [24]McCall MN, Kent OA, Yu J, Fox-Talbot K, Zaiman AL, Halushka MK. 2011 MicroRNA profiling of diverse endothelial cell types. BMC Med. Genom 4: 78 PMC3223144 22047531
  22. [25]Haider BA, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK. 2014 A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLOS ONE 9: e89565 24586876 PMC3935874
  23. [26]Juzenas S, Venkatesh G, Hubenthal M, Hoeppner MP, Du ZG, 2017 A comprehensive, cell specific microRNA catalogue of human peripheral blood. Nucleic Acids Res. 45: 9290– 301 28934507 PMC5766192
  24. [27]van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, 2009 A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev. Cell 17: 662– 73 19922871 PMC2796371
  25. [28]Das S, Halushka MK. 2015 Extracellular vesicle microRNA transfer in cardiovascular disease. Cardiovasc. Pathol 24: 199– 206 25958013
  26. [29]Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, de Marzo AM, 2018 Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci. Rep 8: 7189 29739972 PMC5940660
  27. [30]Stern AD, Alexander BM, Chandra A. 2018 Innovation incentives and biomarkers. Clin. Pharmacol. Ther 103: 34– 36 29034452
  28. [31]Antman EM. 2018 The introduction and clinical use of cardiac-specific troponin assays. Clin. Pharmacol. Ther 103: 31– 33 28755397
  29. [32]Streng AS, Jacobs LH, Schwenk RW, Cardinaels EP, Meex SJ, 2014 Cardiac troponin in ischemic cardiomyocytes: intracellular decrease before onset of cell death. Exp. Mol. Pathol 96: 339– 45 24607416
  30. [33]Bingisser R, Cairns C, Christ M, Hausfater P, Lindahl B, 2012 Cardiac troponin: a critical review of the case for point-of-care testing in the ED. Am. J. Emerg. Med 30: 1639– 49 22633720
  31. [34]White H, Thygesen K, Alpert JS, Jaffe A. 2014 Universal MI definition update for cardiovascular disease. Curr. Cardiol. Rep 16: 492 24803385
  32. [35]Carey RM, Whelton PK. 2018 Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann. Intern. Med 168: 351– 58 29357392
  33. [36]Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, 2018 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71: e13– 115 29133356
  34. [37]Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, 2005 Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant 24: 1710– 20 16297770
  35. [38]Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, 2013 The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant 32: 1147– 62 24263017
  36. [39]Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, 2010 Gene-expression profiling for rejection surveillance after cardiac transplantation. N. Engl. J. Med 362: 1890– 900 20413602
  37. [40]De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, 2014 Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci. Transl. Med 6: 241ra77 PMC4326260 24944192
  38. [41]Kittleson MM, Skojec DV, Wittstein IS, Champion HC, Judge DP, 2009 The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients. J. Heart Lung Transplant. 28: 704– 9 19560699
  39. [42]Halushka MK, Mitchell RN, Padera RF. 2016 Heart failure therapies: new strategies for old treatments and new treatments for old strategies. Cardiovasc. Pathol 25: 503– 11 27619734
  40. [43]Pollack A, Kontorovich AR, Fuster V, Dec GW. 2015 Viral myocarditis—diagnosis, treatment options, and current controversies. Nat. Rev. Cardiol 12: 670– 80 26194549
  41. [44]Chow LH, Radio SJ, Sears TD, McManus BM. 1989 Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J. Am. Coll. Cardiol 14: 915– 20 2794278
  42. [45]Nichols GA, Hillier TA, Erbey JR, Brown JB. 2001 Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24: 1614– 19 11522708
  43. [46]Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlof B, 2005 Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am. J. Cardiol 96: 1530– 36 16310435
  44. [47]Coffey S, Williams MJ, Phillips LV, Jones GT. 2015 Circulating microRNA profiling needs further refinement before clinical use in patients with aortic stenosis. J. Am. Heart Assoc 4: e002150 26304936 PMC4599470
  45. [49]Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, 1992 Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644– 55 1303622
  46. [50]Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, 2016 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315: 801– 10 26903338 PMC4968574
  47. [52]Tang BM, Eslick GD, Craig JC, McLean AS. 2007 Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect. Dis 7: 210– 17 17317602
  48. [53]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, 2008 Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105: 10513– 18 18663219 PMC2492472
  49. [54]Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. 2012 Comparing the microRNA spectrum between serum and plasma. PLOS ONE 7: e41561 22859996 PMC3409228
  50. [56]Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, 2013 Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLOS ONE 8: e64795 23762257 PMC3676411
  51. [57]Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, 2014 Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat. Methods 11: 809– 15 24973947
  52. [58]Schwarzenbach H, da Silva AM, Calin G, Pantel K. 2015 Data normalization strategies for microRNA quantification. Clin. Chem 61: 1333– 42 26408530 PMC4890630
  53. [59]Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, 2014 Human platelet microRNA–mRNA networks associated with age and gender revealed by integrated plateletomics. Blood 123: e37– 45 24523238 PMC3990915
  54. [60]Guo L, Liang T, Yu J, Zou Q. 2016 A comprehensive analysis of miRNA/isomiR expression with gender difference. PLOS ONE 11: e0154955 27167065 PMC4864079
  55. [62]Sredni ST, Gadd S, Jafari N, Huang CC. 2011 A parallel study of mRNA and microRNA profiling of peripheral blood in young adult women. Front. Genet 2: 49 22303345 PMC3268602
  56. [63]Heegaard NH, Carlsen AL, Lilje B, Ng KL, Ronne ME, 2016 Diurnal variations of human circulating cell-free micro-RNA. PLOS ONE 11: e0160577 27494182 PMC4975411
  57. [64]Baras AS, Mitchell CJ, Myers JR, Gupta S, Weng LC, 2015 miRge—a multiplexed method of processing small RNA-seq data to determine microRNA entropy. PLOS ONE 10: e0143066 26571139 PMC4646525
  58. [65]Witwer KW. 2015 Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin.Chem 61: 56– 63 25391989
  59. [66]Becker N, Lockwood CM. 2013 Pre-analytical variables in miRNA analysis. Clin. Biochem 46: 861– 68 23466658
  60. [67]Khan J, Lieberman JA, Lockwood CM. 2017 Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs. Clin. Chem. Lab. Med 55: 608– 21 28306519
  61. [68]Ai J, Zhang R, Li Y, Pu J, Lu Y, 2010 Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun 391: 73– 77 19896465
  62. [69]Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, 2010 Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet 3: 499– 506 20921333
  63. [70]Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, 2010 Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J 31: 659– 66 20159880
  64. [71]Li YQ, Zhang MF, Wen HY, Hu CL, Liu R, 2013 Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics 68: 75– 80 PMC3552456 23420161
  65. [72]Oerlemans MI, Mosterd A, Dekker MS, de Vrey EA, van Mil A, 2012 Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol. Med 4: 1176– 85 23023917 PMC3494874
  66. [73]Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, 2012 Use of circulating microRNAs to diagnose acute myocardial infarction. Clin. Chem 58: 559– 67 22252325
  67. [74]Bai R, Yang Q, Xi R, Li L, Shi D, Chen K. 2017 miR-941 as a promising biomarker for acute coronary syndrome. BMC Cardiovasc. Disord 17: 227 28830367 PMC5568367
  68. [75]Pilbrow AP, Cordeddu L, Cameron VA, Frampton CM, Troughton RW, 2014 Circulating miR-323–3p and miR-652: candidate markers for the presence and progression of acute coronary syndromes. Int. J. Cardiol 176: 375– 85 25124998
  69. [76]Coskunpinar E, Cakmak HA, Kalkan AK, Tiryakioglu NO, Erturk M, Ongen Z. 2016 Circulating miR-221–3p as a novel marker for early prediction of acute myocardial infarction. Gene 591: 90– 96 27374153
  70. [77]He F, Lv P, Zhao X, Wang X, Ma X, 2014 Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol. Cell. Biochem 394: 137– 44 24833470
  71. [78]Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, 2012 Prospective study on circulating microRNAs and risk of myocardial infarction. J. Am. Coll. Cardiol 60: 290– 99 22813605
  72. [79]Chistiakov DA, Orekhov AN, Bobryshev YV. 2016 The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. J. Mol. Cell. Cardiol 97: 47– 55 27180261
  73. [80]Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, 2010 Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res 107: 810– 17 20651284
  74. [81]Van Aelst LN, Summer G, Li S, Gupta SK, Heggermont W, 2016 RNA profiling in human and murine transplanted hearts: identification and validation of therapeutic targets for acute cardiac and renal allograft rejection. Am. J. Transplant 16: 99– 110 PMC5054886 26249758
  75. [82]Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, 2014 MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur. Heart J 35: 3194– 202 25176944
  76. [83]Sukma Dewi I, Hollander Z, Lam KK, McManus JW, Tebbutt SJ, 2017 Association of serum miR-142–3p and miR-101–3p levels with acute cellular rejection after heart transplantation. PLOS ONE 12: e0170842 28125729 PMC5268768
  77. [84]Sukma Dewi I, Torngren K, Gidlof O, Kornhall B, Ohman J. 2013 Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. J. Heart Lung Transplant 32: 463– 66 23384889
  78. [85]Neumann A, Napp LC, Kleeberger JA, Benecke N, Pfanne A, 2017 MicroRNA 628–5p as a novel biomarker for cardiac allograft vasculopathy. Transplantation 101: e26– 33 27653298
  79. [86]Wang D, Li T, Cui H, Zhang Y. 2016 Analysis of the indicating value of cardiac troponin I, tumor necrosis factor-α, interleukin-18, miR-1 and miR-146b for viral myocarditis among children. Cell. Physiol. Biochem 40: 1325– 33 27997912
  80. [87]Gildea JJ, Carlson JM, Schoeffel CD, Carey RM, Felder RA. 2013 Urinary exosome miRNome analysis and its applications to salt sensitivity of blood pressure. Clin. Biochem 46: 1131– 34 23726803 PMC3786136
  81. [88]Qi H, Liu Z, Liu B, Cao H, Sun W, 2017 micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension. Medicine 96: e6417 28445253 PMC5413218
  82. [89]Huang YQ, Huang C, Chen JY, Li J, Feng YQ. 2016 The association of circulating miR-30a, miR-29 and miR-133 with white-coat hypertension. Biomark. Med 10: 1231– 39 27924640
  83. [90]Cengiz M, Karatas OF, Koparir E, Yavuzer S, Ali C, 2015 Differential expression of hypertension-associated microRNAs in the plasma of patients with white coat hypertension. Medicine 94: e693 25837765 PMC4554020
  84. [91]Cengiz M, Yavuzer S, Kiliçkiran Avci B, Yürüyen M, Yavuzer H, 2015 Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin. Exp. Hypertens 37: 643– 49 26114349
  85. [92]Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, 2012 Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab 97: E2271– 76 23032062
  86. [93]Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. 2014 Differential expression of vascular smooth muscle–modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. J. Hum. Hypertens 28: 510– 16 24284386
  87. [94]Marques FZ, Charchar FJ. 2015 microRNAs in essential hypertension and blood pressure regulation. Adv. Exp. Med. Biol 888: 215– 35 26663185
  88. [95]de Gonzalo-Calvo D, van der Meer RW, Rijzewijk LJ, Smit JW, Revuelta-Lopez E, 2017 Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci. Rep 7: 47 28246388 PMC5428350
  89. [96]Rawal S, Ram TP, Coffey S, Williams MJ, Saxena P, 2016 Differential expression pattern of cardiovascular microRNAs in the human type-2 diabetic heart with normal ejection fraction. Int. J. Cardiol 202: 40– 43 26386917
  90. [97]Leon LE, Rani S, Fernandez M, Larico M, Calligaris SD. 2016 Subclinical detection of diabetic cardiomyopathy with microRNAs: challenges and perspectives. J. Diabetes Res 2016: 6143129 26770988 PMC4684873
  91. [98]Lu H, Buchan RJ, Cook SA. 2010 MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc. Res 86: 410– 20 20080987
  92. [99]Guo R, Nair S. 2017 Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Biochim. Biophys. Acta 1863: 2070– 77 PMC5475364 28344129
  93. [100]Liu X, Liu S. 2017 Role of microRNAs in the pathogenesis of diabetic cardiomyopathy. Biomed. Rep 6: 140– 45 28357065 PMC5351040
  94. [101]Gilca GE, Stefanescu G, Badulescu O, Tanase DM, Bararu I, Ciocoiu M. 2017 Diabetic cardiomyopathy: current approach and potential diagnostic and therapeutic targets. J. Diabetes Res 2017: 1310265 28421204 PMC5379137
  95. [102]Copier CU, Leon L, Fernandez M, Contador D, Calligaris SD. 2017 Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy. Sci. Rep 7: 13514 29044172 PMC5647433
  96. [103]Garcia R, Villar AV, Cobo M, Llano M, Martin-Duran R, 2013 Circulating levels of miR-133a predict the regression potential of left ventricular hypertrophy after valve replacement surgery in patients with aortic stenosis. J. Am. Heart Assoc 2: e000211 23948643 PMC3828793
  97. [105]Beaumont J, Lopez B, Ravassa S, Hermida N, Jose GS, 2017 MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Sci. Rep 7: 40696 28091585 PMC5238428
  98. [106]Fabiani I, Scatena C, Mazzanti CM, Conte L, Pugliese NR, 2016 Micro-RNA-21 (biomarker) and global longitudinal strain (functional marker) in detection of myocardial fibrotic burden in severe aortic valve stenosis: a pilot study. J. Transl. Med 14: 248 27567668 PMC5002330
  99. [107]Villar AV, Garcia R, Merino D, Llano M, Cobo M, 2013 Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int. J. Cardiol 167: 2875– 81 22882958
  100. [109]Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, 2015 Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur. J. Heart Fail 17: 393– 404 25619197
  101. [110]Watson CJ, Gupta SK, O’ Connell E, Thum S, Glezeva N, 2015 MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur. J. Heart Fail 17: 405– 15 25739750 PMC4418397
  102. [111]Lu Y, Zhang Y, Wang N, Pan Z, Gao X, 2010 MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122: 2378– 87 21098446
  103. [112]McManus DD, Lin H, Tanriverdi K, Quercio M, Yin X, 2014 Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm 11: 663– 69 24444445 PMC4219255
  104. [113]Liu Z, Zhou C, Liu Y, Wang S, Ye P, 2012 The expression levels of plasma microRNAs in atrial fibrillation patients. PLOS ONE 7: e44906 23028671 PMC3445571
  105. [114]Natsume Y, Oaku K, Takahashi K, Nakamura W, Oono A, 2018 Combined analysis of human and experimental murine samples identified novel circulating microRNAs as biomarkers foratrial fibrillation. Circ. J 82: 965– 73 29398686
  106. [115]Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, 2013 MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127: 1466– 75 23459615
  107. [117]Benz F, Roy S, Trautwein C, Roderburg C, Luedde T. 2016 Circulating microRNAs as biomarkers for sepsis. Int. J. Mol. Sci 17: 78 PMC4730322 26761003
  108. [118]Dumache R, Rogobete AF, Bedreag OH, Sarandan M, Cradigati AC, 2015 Use of miRNAs as biomarkers in sepsis. Anal. Cell. Pathol 2015: 186716 PMC4499375 26221578
  109. [119]Kingsley SMK, Bhat BV. 2017 Role of microRNAs in sepsis. Inflamm. Res 66: 553– 69 28258291
  110. [120]Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, 2009 MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLOS ONE 4: e7405 19823581 PMC2756627
  111. [121]Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Scholten D, 2013 Circulating microRNA-150 serum levels predict survival in patients with critical illness and sepsis. PLOS ONE 8: e54612 23372743 PMC3555785
  112. [122]Ma Y, Vilanova D, Atalar K, Delfour O, Edgeworth J, 2013 Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis. PLOS ONE 8: e75918 24146790 PMC3797812
  113. [123]Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, 2010 Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem. Biophys. Res. Commun 394: 184– 88 20188071
  114. [124]Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie L. 2012 Serum microRNA signatures identified by Solexa sequencing predict sepsis patients’ mortality: a prospective observational study. PLOS ONE 7: e38885 22719975 PMC3376145
  115. [125]Wang HJ, Zhang PJ, Chen WJ, Feng D, Jia YH, Xie LX. 2012 Four serum microRNAs identified as diagnostic biomarkers of sepsis. J. Trauma Acute Care Surg. 73: 850– 54 23026916
  116. [126]Wu Y, Li C, He Y, Li Q, Wang G, 2014 [Relationship between expression of microRNA and inflammatory cytokines plasma level in pediatric patients with sepsis]. Zhonghua Er Ke Za Zhi 52: 28– 33 (In Chinese) 24680405
  117. [127]Wang L, Wang HC, Chen C, Zeng J, Wang Q, 2013 Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients. Exp. Ther. Med 5: 1101– 04 23596477 PMC3627686
  118. [129]Benz F, Tacke F, Luedde M, Trautwein C, Luedde T, 2015 Circulating microRNA-223 serum levels do not predict sepsis or survival in patients with critical illness. Dis. Markers 2015: 384208 25810564 PMC4355123
  119. [130]Taganov KD, Boldin MP, Chang KJ, Baltimore D. 2006 NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. PNAS 103: 12481– 86 16885212 PMC1567904
  120. [131]Witwer KW, Soekmadji C, Hill AF, Wauben MH, Buzas EI, 2017 Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility. J. Extracell. Vesicles 6: 1396823 29184626 PMC5698937
  121. [132]Chevillet JR, Lee I, Briggs HA, He Y, Wang K. 2014 Issues and prospects of microRNA-based biomarkers in blood and other body fluids. Molecules 19: 6080– 105 24830712 PMC6271291
  122. [133]Sunderland N, Skroblin P, Barwari T, Huntley RP, Lu R, 2017 MicroRNA biomarkers and platelet reactivity: the clot thickens. Circ. Res 120: 418– 35 28104774
  123. [134]Wang H, Meng K, Chen W, Feng D, Jia Y, Xie L. 2012 Serum miR-574–5p: a prognostic predictor ofsepsis patients. Shock 37: 263– 67 22344312
  124. [135]Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie LX. 2012 Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. Clin. Chem. Lab. Med 50: 1423– 28 22868808
  125. [136]Sun X, Icli B, Wara AK, Belkin N, He S, 2012 MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J. Clin. Investig 122: 1973– 90 22622040 PMC3366408
  126. [137]Wang H, Yu B, Deng J, Jin Y, Xie L. 2014 Serum miR-122 correlates with short-term mortality in sepsis patients. Crit. Care 18: 704 25672224 PMC4262971
  127. [138]How CK, Hou SK, Shih HC, Huang MS, Chiou SH, 2015 Expression profile of microRNAs in Gram-negative bacterial sepsis. Shock 43: 121– 27 25394245
  128. [139]Goodwin AJ, Guo C, Cook JA, Wolf B, Halushka PV, Fan H. 2015 Plasma levels of microRNA are altered with the development of shock in human sepsis: an observational study. Crit. Care 19: 440 26683209 PMC4699334
  129. [140]Caserta S, Kern F, Cohen J, Drage S, Newbury SF, Llewelyn MJ. 2016 Circulating plasma microRNAs can differentiate human sepsis and systemic inflammatory response syndrome (SIRS). Sci. Rep 6: 28006 27320175 PMC4913253

Cited by

Sorted by citations

Authors
Halushka, P. V., Goodwin, A. J., & Halushka, M. K.
Affiliations
  • Department of Pharmacology, South Carolina Clinical and Translational Research Institute, Medical University of South Carolina, Charleston, South Carolina 29425, USA;
  • Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA;
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA;
Venue
Annual Review of Pathology: Mechanisms of Disease
Publisher
Annual Reviews
Published
2019-01-24
Volume
14
Issue
1
Pages
211-238
ISSN
  • 1553-4006
  • 1553-4014
DOI
10.1146/annurev-pathmechdis-012418-012827
PMC
PMC6442682
Cited by
61
References
10
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review